Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Earnings for Collegium Pharmaceutical, Inc. (COLL)
Earnings in 2023 (TTM): $75.73 M
According to Collegium Pharmaceutical, Inc.'s latest financial reports the company's current earnings (TTM) are $75.73 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Collegium Pharmaceutical, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $75.73 M | $48.16 M |
| 2022 | $-28,847,000 | $-25,002,000 |
| 2021 | $-3,374,000 | $71.52 M |
| 2020 | $27.58 M | $26.75 M |
| 2019 | $-22,722,000 | $-8,148,000 |
| 2018 | $-39,128,000 | $-39,128,000 |
| 2017 | $-74,865,000 | $-74,865,000 |
| 2016 | $-94,176,000 | $-94,176,000 |
| 2015 | $-27,255,000 | $-27,255,000 |
| 2014 | $-17,917,000 | $-17,917,000 |
| 2013 | $-16,197,000 | $-16,197,000 |